Corrigendum to The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutations [Human Molecular Genetics, 22:18, 2013, 3667-3679], doi:10.1093/hmg/ddt216;The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutations

Human Molecular Genetics

Volumn 22, Issue 18, 2013, Pages 3667-3679

  Dunmore, Benjamin J ^a   Drake, Kylie M ^b   Upton, Paul D ^a   Toshner, Mark R ^a   Aldred, Micheala A ^b,c   Morrell, Nicholas W ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b LERNER RESEARCH INSTITUTE   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BMPR II PROTEIN; BONE MORPHOGENETIC PROTEIN 9; CHLOROQUINE; INHIBITOR OF DIFFERENTIATION 1; MEMBRANE PROTEIN; MESSENGER RNA; RNA DIRECTED DNA POLYMERASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; BIOTINYLATION; CELL SURFACE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENDOTHELIUM CELL; EXON; FEMALE; GENE DELETION; HELA CELL; HUMAN; HUMAN CELL; INHIBITION KINETICS; MICROVASCULAR ENDOTHELIAL CELL; MOLECULAR DYNAMICS; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; PULMONARY HYPERTENSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STEADY STATE; SURFACE PROPERTY; UBIQUITINATION; WESTERN BLOTTING;

BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; CELL LINE; CELL MEMBRANE; CELLS, CULTURED; CHLOROQUINE; ENDOTHELIAL CELLS; GROWTH DIFFERENTIATION FACTORS; HUMANS; HYPERTENSION, PULMONARY; LYSOSOMES; MUTATION; PULMONARY ARTERY; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSCRIPTION, GENETIC;

EID: 84883010729     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt492     Document Type: Erratum

References (53)

1. Morrell, N.W., Adnot, S., Archer, S.L., Dupuis, J., Jones, P.L., MacLean, M.R., McMurtry, I.F., Stenmark, K.R., Thistlethwaite, P.A., Weissmann, N., Yuan, J.X. and Weir, E.K. (2009) Cellular and molecular basis of pulmonary arterial hypertension. J. Am. Coll. Cardiol., 54, S20-S31.
2. Davies, R.J. and Morrell, N.W. (2006) Molecular mechanisms of pulmonary arterial hypertension: role of mutations in the bone morphogenetic protein type II receptor. Chest, 134, 1271-1277.
3. Morrell, N.W. (2006) Pulmonary hypertension due to bmpr2 mutation: A new paradigm for tissue remodeling? Proc. Am. Thorac. Soc., 3, 680-686.
4. The International PPHCLane, K.B., Machado, R.D., Pauciulo, M.W., Thomson, J.R., Philips, J.A., Loyd, J.E., Nichols, W.C. and Trembath, R.C. (2000) Heterozygous germ-line mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat. Genet., 26, 81-84.
5. Machado, R.D., Pauciulo, M.W., Thomson, J.R., Lane, K.B., Morgan, N.V., Wheeler, L., Phillips, J.A 3rd., Newman, J., Williams, D., Galie, N. et al. (2001)BMPR2haploinsufficiency as the inherited molecular mechanismfor primary pulmonary hypertension. Am. J. Hum. Genet., 68, 92-102.
6. Thomson, J.R., Machado, R.D., Pauciulo, M.W., Morgan, N.V., Humbert, M., Elliot, G.C., Ward, K., Yacoub, M., Mikhail, G., Rogers, P. et al. (2000) Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-b family. J. Med. Genet., 37, 741-745.
7. Yang, X., Long, L., Southwood, M., Rudarakanchana, N., Upton, P.D., Jeffery, T.K., Atkinson, C., Chen, H., Trembath, R.C. and Morrell, N.W. (2005) Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ. Res., 96, 1053-1063.
8. Yang, J., Davies, R.J., Southwood, M., Long, L., Yang, X., Sobolewski, A., Upton, P.D., Trembath, R.C. and Morrell, N.W. (2008) Mutations in bone morphogenetic protein type II receptor cause dysregulation of id gene expression in pulmonary artery smooth muscle cells: implications for familial pulmonary arterial hypertension. Circ. Res., 102, 1212-1221.
9. Toshner, M., Voswinckel, R., Southwood, M., Al-Lamki, R., Howard, L.S., Marchesan, D., Yang, J., Suntharalingam, J., Soon, E., Exley, A. et al. (2009) Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med., 180, 780-787.
10. Atkinson, C., Stewart, S., Upton, P.D., Machado, R., Thomson, J.R., Trembath, R.C. and Morrell, N.W. (2002) Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation, 105, 1672-1678.
11. Dewachter, L., Adnot, S., Guignabert, C., Tu, L., Marcos, E., Fadel, E., Humbert, M., Dartevelle, P., Simonneau, G., Naeije, R. and Eddahibi, S. (2009) Bone morphogenetic protein signalling in heritable versus idiopathic pulmonary hypertension. Eur. Respir. J., 34, 1100-1110.
12. Long, L., MacLean, M.R., Jeffery, T.K., Morecroft, I., Yang, X., Rudarakanchana, N., Southwood, M., James, V., Trembath, R.C. and Morrell, N.W. (2006) Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ. Res., 98, 818-827.
13. Long, L., Crosby, A., Yang, X., Southwood, M., Upton, P.D., Kim, D.K. and Morrell, N.W. (2009) Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation, 119, 566-576.
14. Reynolds, A.M., Holmes, M.D., Danilov, S.M. and Reynolds, P.N. (2012) Targeted gene delivery ofBMPR-2attenuates pulmonary hypertension. Eur. Respir. J., 39, 329-343.
15. Durrington, H.J., Upton, P.D., Hoer, S., Boname, J., Dunmore, B.J., Yang, J., Crilley, T.K., Butler, L.M., Blackbourn, D.J., Nash, G.B., Lehner, P.J. and Morrell, N.W. (2010) Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor type II. J. Biol. Chem., 285, 37641-37649.
16. Solomon, V.R. and Lee, H. (2009) Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur. J. Pharmacol., 625, 220-233.
17. Dalby, K.N., Tekedereli, I., Lopez-Berestein, G. and Ozpolat, B. (2010) Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy, 6, 322-329.
18. Augustijns, P., Geusens, P. and Verbeke, N. (1992) Chloroquine levels in blood during chronic treatment of patients with rheumatoid arthritis. Eur. J. Clin. Pharmacol., 42, 429-433.
19. Ben-Zvi, I., Kivity, S., Langevitz, P. and Shoenfeld, Y. (2012) Hydroxychloroquine: from malaria to autoimmunity. Clin. Rev. Aller. Immunol., 42, 145-153.
20. Kalia, S. and Dutz, J.P. (2007)New concepts in antimalarial use and mode of action in dermatology. Dermatol. Ther., 20, 160-174.
21. Long, L., Yang, X., Southwood, M., Lu, J., Marciniak, S.J., Dunmore, B.J. and Morrell, N.W.(2013) Chloroquine prevents progression of experimental pulmonary hypertension via inhibition of autophagy and lysosomal BMPR-II degradation. Circ. Res., 112, 1159-1170.
22. Van Den Driesche, S., Mummery, C.L. and Westermann, C.J. (2003) Hereditary hemorrhagic telangiectasia: an update on transforming growth factor beta signaling in vasculogenesis and angiogenesis. Cardiovasc. Res., 58, 20-31.
23. David, L., Mallet, C., Mazerbourg, S., Feige, J.J. and Bailly, S. (2007) Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood, 109, 1953-1961.
24. Scharpfenecker, M., van Dinther, M., Liu, Z., van Bezooijen, R.L., Zhao, Q., Pukac, L., Löwik, C.W. and ten Dijke, P. (2007) BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J. Cell Sci., 120, 964-972.
25. David, L., Mallet, C., Keramidas, M., Lamandé, N., Gasc, J.M., Dupuis-Girod, S., Plauchu, H., Feige, J.J. and Bailly, S. (2008) Bone morphogenetic protein-9 is a circulating vascular quiescence factor. Circ. Res., 102, 914-922.
26. Upton, P.D., Davies, R.J., Trembath, R.C. and Morrell, N.W. (2009) Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells. J. Biol. Chem., 284, 15794-15804.
27. Trembath, R.C., Thomson, J.R., Machado, R.D., Morgan, N.V., Atkinson, C., Winship, I., Simonneau, G., Galie, N., Loyd, J.E., Humbert, M. et al. (2001) Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N. Engl. J. Med., 345, 325-334.
28. Davis, B.N., Hilyard, A.C., Lagna, G. and Hata, A. (2008) SMAD proteins control DROSHA-mediated microRNA maturation. Nature, 454, 56-61.
29. Davis, B.N., Hilyard, A.C., Nguyen, P.H., Lagna, G. and Hata, A. (2010) Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha. Mol. Cell., 39, 373-384.
30. Drake, K.M., Zygmunt, D., Mavrakis, L., Harbor, P., Wang, L., Comhair, S.A., Erzurum, S.C. and Aldred, M.A.(2011) AlteredMicroRNAprocessing in heritable pulmonary arterial hypertension: an important role for Smad-8. Am. J. Respir. Crit. Care Med., 184, 1400-1408.
31. Forgac, M. (2007) Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology. Nat. Rev. Mol. Cell Biol., 8, 917-929.
32. Dröse, S. and Altendorf, K. (1997) Bafilomycins and concanamycins as inhibitors of V-ATPases and P-ATPases. J. Exp. Biol., 200, 1-8.
33. Yoshimori, T., Yamamoto, A., Moriyama, Y., Futai, M. and Tashiro, Y. (1991) Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J. Biol. Chem., 266, 17707-17712.
34. Kaufmann, A.M. and Krise, J.P. (2007) Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications. J. Pharm. Sci., 96, 729-746.
35. de Duve, C., de Barsy, T., Poole, B., Trouet, A., Tulkens, P. and Van Hoof, F. (1974) Commentary. Lysosomotropic agents. Biochem. Pharmacol., 23, 2495-2531.
36. Ohkuma, S. and Poole, B. (1978) Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc. Natl Acad. Sci. USA, 75, 3327-3331.
37. Massagué, J. and Kelly, B. (1986) Internalization of transforming growth factor-beta and its receptor in BALB/c 3T3 fibroblasts. J. Cell Physiol., 128, 216-222.
38. Teng, R.J., Du, J., Welak, S., Guan, T., Eis, A., Shi, Y. and Konduri, G.G. (2012) Cross-talk between NADPH oxidase and autophagy in pulmonary artery endothelial cells with intrauterine persistent pulmonary hypertension. Am. J. Physiol. Lung. Cell Mol. Physiol., 302, L651-663.
39. Hartung, A., Bitton-Worms, K., Rechtman, M.M., Wenzel, V., Boergermann, J.H., Hassel, S., Henis, Y.I. and Knaus, P. (2006) Different routes of bone morphogenic protein (BMP) receptor endocytosis influence BMP signaling. Mol. Cell Biol., 26, 7791-7805.
40. Machado, R.D., Aldred, M.A., James, V., Harrison, R.E., Patel, B., Schwalbe, E.C., Gruenig, E., Janssen, B., Koehler, R., Seeger, W. et al. (2006) Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum. Mutat., 27, 121-132.
41. Liu, D., Wang, J., Kinzel, B., Müeller, M., Mao, X., Valdez, R., Liu, Y. and Li, E. (2007) Dosage-dependent requirement of BMP type II receptor for maintenance of vascular integrity. Blood, 110, 1502-1510.
42. Doody, A.M., Antosh, A.L. and Brown, W.J. (2009) Cytoplasmic phospholipase A2 antagonists inhibit multiple endocytic membrane trafficking pathways. Biochem. Biophys. Res. Commun., 388, 695-699.
43. Bragdon, B., Thinakaran, S., Bonor, J., Underhill, T.M., Petersen, N.O. and Nohe, A. (2009) FRET reveals novel protein-receptor interaction of bone morphogenetic proteins receptors and adaptor protein 2 at the cell surface. Biophys. J., 97, 1428-1435.
44. Ramos, M., Lamé, M.W., Segall, H.J. and Wilson, D.W. (2006) The BMP type II receptor is located in lipid rafts, including caveolae, of pulmonary endothelium in vivo and in vitro. Vasc. Pharmacol., 44, 50-59.
45. Wertz, J.W. and Bauer, P.M. (2008) Caveolin-1 regulates BMPRII localization and signaling in vascular smooth muscle cells. Biochem. Biophys. Res. Commun., 375, 557-561.
46. Zhao, Y.Y., Liu, Y., Stan, R.V., Fan, L., Gu, Y., Dalton, N., Chu, P.H., Peterson, K., Ross, J. Jr and Chien, K.R. (2002) Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc. Natl Acad. Sci. USA, 99, 11375-11380.
47. Austin, E.D., Ma, L., Leduc, C., Berman Rosenzweig, E., Borczuk, A., Phillips, J.A. 3rd., Palomero, T., Sumazin, P., Kim, H.R., Talati, M.H. et al. (2012) Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension. Circ. Cardiovasc. Genet., 5, 336-343.
48. Masri, F.A., Xu, W., Comhair, S.A., Asosingh, K., Koo, M., Vasanji, A., Drazba, J., Anand-Apte, B. and Erzurum, S.C. (2007) Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. Am. J. Physiol. Lung. Cell Mol. Physiol., 293, L548-L554.
49. Comhair, S.A., Xu, W., Mavrakis, L., Aldred, M.A., Asosingh, K. and Erzurum, S.C. (2012) Human primary lung endothelial cells in culture. Am. J. Respir. Cell Mol. Biol., 46, 723-730.
50. Morrell, N.W., Yang, X., Upton, P.D., Jourdan, K.B., Morgan, N., Sheares, K.K. and Trembath, R.C. (2001) Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation, 104, 790-795.
51. Sobolewski, A., Rudarakanchana, N., Upton, P.D., Yang, J., Crilley, T.K., Trembath, R.C. and Morrell, N.W. (2008) Failure of bone morphogenetic protein receptor trafficking in pulmonary arterial hypertension: potential for rescue. Hum. Mol. Genet., 17, 3180-3190.
52. Livak, K.J. and Schmittgen, T.D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods, 25, 402-408.
53. Rennolds, J., Boyaka, P.N., Bellis, S.L. and Cormet-Boyaka, E. (2008) Low temperature induces the delivery of mature and immature CFTR to the plasma membrane. Biochem. Biophys. Res. Commun., 366, 1025-1029.